Hospital San Cecilio group (Granada)
The Hospital San Cecilio group was started in 2000 and joined RIS in 2004 as a clinical associate group and upgraded to a core group in 2012. The group is actively involved in research on viral resistance in Spain in the field of HIV and hepatitis C. At the national level, the group co-coordinates the WP of resistance & subtypes of the RIS, actively participates in GEHEP (Spanish Group for the Study of Hepatitis-SEIMC), is leading clinical research on human papillomaviruses, and is also involved in research on microbiome and metagenomics. The group actively participates in international collaborations related to resistance to antivirals and hepatitis C (CHAIN, ART collaboration, PLATO II, Coronet, SPREAD, EucoHIV, Eurocoord, CAPRE, HEPC-Care, Shared).
The areas of research in which the group is currently involved are:
- Resistance to antiretrovirals: the group leads the research on transmitted drug resistance in CoRIS. At present research is focused on TDR to first line drugs. The group is conducting the surveillance programme on TDR to integrase inhibitors.
- Resistance to direct acting antiviral drugs (DAAs) against hepatitis C virus: the group is leading DAA resistance studies in Spain, both at baseline and failures, giving service to many groups from RIS. The group is actively involved in characterising reinfection events, and how to apply phylogenetic analysis tools for this topic, and also to evaluate the introduction of HCV in Spain, its spread across the country, and from Spain to other parts of the world.
- Human papillomavirus in HIV patients: the group has a leadership in the evaluation of the efficacy of vaccination against HPV in HIV patients and on clinical and epidemiological studies of HPV in HIV positive patients
- Microbiome analysis: the group has numerous collaborations on microbiome analysis related with probiotics, periodontal diseases, digestive diseases, and other areas (trasplant, basic research)